ISDA

Entry Detail

PDB ID:

4RLL

Keywords:

Title:

Crystal structure of human CK2alpha in complex with the ATP-competitive inhibitor 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2014-10-17

Release Date:

2014-12-17

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.85 Å

R-Value Free:

0.21

R-Value Work:

0.16

R-Value Observed:

0.17

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Casein kinase II subunit alpha
Chain IDs:A
Chain Length:335
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P68400 Pfam ID:PF00069 EC:2.7.11.1

Ligand Molecules

E91

GOL

Primary Citation

Protein kinase CK2 inhibition is associated with the destabilization of HIF-1 alpha in human cancer cells.

Guerra, B, Rasmussen, T.D, Schnitzler, A, Jensen, H.H, Boldyreff, B.S, Miyata, Y, Marcussen, N, Niefind, K, Issinger, O.G.Show

Cancer Lett 356 751 761 (2015)

PMID: 25449433 DOI: 10.1016/j.canlet.2014.10.026

Abstact

Screening for protein kinase CK2 inhibitors of the structural diversity compound library (DTP NCI/NIH) led to the discovery of 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl]benzoic acid (E9). E9 induces apoptotic cell death in various cancer cell lines and upon hypoxia, the compound suppresses CK2-catalyzed HSP90/Cdc37 phosphorylation and induces HIF-1α degradation. Furthermore, E9 exerts a strong anti-tumour activity by inducing necrosis in murine xenograft models underlining its potential to be used for cancer treatment in future clinical studies. Crystal structure analysis of human and maize CK2α in complex with E9 reveals unique binding properties of the inhibitor to the enzyme, accounting for its affinity and selectivity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures